|67.44||+0.1800||+0.27%||Vol 1.84M||1Y Perf 1.88%|
|Mar 24th, 2023 11:35 DELAYED|
|0.48 0.71%||- -|
|Target Price||77.30||Analyst Rating||Strong Buy 1.50|
|Potential %||14.71||Finscreener Ranking||+ 37.96|
|Insiders Trans % 3/6/12 mo.||-/-/-||Value Ranking||☆ 28.23|
|Insiders Value % 3/6/12 mo.||-/-/-||Growth Ranking||★★+ 48.50|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-/-||Income Ranking||☆ 21.73|
|Price Range Ratio 52W %||75.96||Earnings Rating||Sell|
|Market Cap||209.04B||Earnings Date||5th May 2023|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Buy|
|Mngmt Effectiveness||Value||Industry||S&P 500||US Markets|
ROE (5Y Avg)
ROE last 12 Months
ROA (5Y Avg)
ROA last 12 Months
ROC (5Y Avg)
ROC last 12 Months
Return on invested Capital Q
Return on invested Capital Y
|Valuation||Value||Industry||S&P 500||US Markets|
|Financial Strength||Value||Industry||S&P 500||US Markets|
|Profitability||Value||Industry||S&P 500||US Markets|
|Revenue||Value||Industry||S&P 500||US Markets|
|Dividends||Value||Industry||S&P 500||US Markets|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||5th May 2023|
|Estimated EPS Next Report||0.84|
|EPS Growth Next 5 Years %||14.70|
|Avg. Weekly Volume||4.17M|
|Avg. Monthly Volume||4.24M|
|Avg. Quarterly Volume||5.00M|
AstraZeneca PLC (NYSE: AZN) stock closed at 67.26 per share at the end of the most recent trading day (a 1.04% change compared to the prior day closing price) with a volume of 4.31M shares and market capitalization of 209.04B. Is a component of NASDAQ 100 indices and it is traded on NYSE exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 76100 people. AstraZeneca PLC CEO is Pascal Soriot.
The one-year performance of AstraZeneca PLC stock is 1.88%, while year-to-date (YTD) performance is -0.8%. AZN stock has a five-year performance of 96.84%. Its 52-week range is between 52.65 and 72.12, which gives AZN stock a 52-week price range ratio of 75.96%
AstraZeneca PLC currently has a PE ratio of 101.70, a price-to-book (PB) ratio of 6.06, a price-to-sale (PS) ratio of 6.01, a price to cashflow ratio of 24.30, a PEG ratio of 2.32, a ROA of 2.21%, a ROC of 4.10% and a ROE of 5.93%. The company’s profit margin is 7.21%, its EBITDA margin is 19.00%, and its revenue ttm is $36.54 Billion , which makes it $11.79 revenue per share.
Of the last four earnings reports from AstraZeneca PLC, there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.84 for the next earnings report. AstraZeneca PLC’s next earnings report date is 05th May 2023.
The consensus rating of Wall Street analysts for AstraZeneca PLC is Strong Buy (1.5), with a target price of $77.3, which is +14.71% compared to the current price. The earnings rating for AstraZeneca PLC stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
AstraZeneca PLC has a dividend yield of 1.28% with a dividend per share of $0.91 and a payout ratio of 93.00%.
AstraZeneca PLC has a Buy technical analysis rating based on Technical Indicators (ADX : 8.53, ATR14 : 1.10, CCI20 : 153.34, Chaikin Money Flow : 0.08, MACD : -0.03, Money Flow Index : 59.11, ROC : 4.62, RSI : 57.13, STOCH (14,3) : 85.75, STOCH RSI : 1.00, UO : 60.67, Williams %R : -14.25), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of AstraZeneca PLC in the last 12-months were: Andreas Rummelt (Sold 7 585 shares of value $989 539 ), Aradhana Sarin (Sold 25 403 shares of value $3 313 401 )
|Analyst Ratings||Current||1 M ago||3 M ago|
|Summary Rating||Strong Buy||Strong Buy||Strong Buy|
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The company sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
CEO: Pascal Soriot
Telephone: +44 2037495000
Address: 1 Francis Crick Avenue, Cambridge CB2 0AA, , GB
Number of employees: 76 100
Fri, 10 Mar 2023 21:15 GMT AstraZeneca (AZN) Receives a Buy from SVB Securities- TipRanks. All rights reserved.
Fri, 10 Feb 2023 12:30 GMT Analysts Are Bullish on Top Healthcare Stocks: AstraZeneca (AZN), AbbVie (ABBV)- TipRanks. All rights reserved.
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.